Browsing tag:

HbA1c


On January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought[…]

Read More

The latest news in the fight against type 2 diabetes highlights Dapagliflozin and Saxagliptin as the latest dazzling duo. Known as the brand name medications Farxiga {Dapagliflozin} and Onglyza {Saxagliptin} these powerhouse drugs have proven themselves in Phase lll trials. Data recently released from the 534 patient, three-arm trial demonstrated that the combination treatment of[…]

Read More

As an anti-diabetic medication and selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2), Dapagliflozin is now approved by the FDA for the treatment of type 2 diabetes mellitus. The Dapagliflozin FDA approval was announced January 13, 2014, as the brand name Farxiga, which is marketed by Bristol-Myers Squibb. The unique ability of Dapagliflozin[…]

Read More

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on March 19, 2013 the initiation of a novel clinical trial for linagliptin. Coined MARLINA, this Phase IIIb trial will evaluate the glycemic efficacy and safety of linagliptin in patients with type 2 diabetes who have prevalent albuminuria. This patient population, suffering from albuminuria, will[…]

Read More

As a treatment for Type 2 diabetes lixisenatide is approved by the EU and currently under review as a New Drug Application {NDA} by the FDA. Sanofi is preparing to launch lixisenatide in the European Union as in the latter of first quarter 2013, with the proprietary name Lyxumia. What makes lixisenatide unique is not[…]

Read More

Sevelamer Hydrochloride, CAS number 152751-57-0 is efficacious when used to treat patients with kidney disease who are on dialysis. As patients with kidney disease have low blood levels of phosphorus, sevelamer binds with phosphorus in patients’ everyday diet, and prevents it from being absorbed into the blood stream. In capsule form, sevelamer is typically taken[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service